LIGAND PHARMACEUTICALS INC - Common Stock (LGND)

Historical Holders from Q1 2014 to Q3 2025

Symbol
LGND on Nasdaq
Type / Class
Equity / Common Stock
Shares outstanding
19.7M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
20.5M
Holdings value
$3.63B
% of all portfolios
0.005%
Grand Portfolio weight change
+0%
Number of holders
307
Number of buys
160
Number of sells
-116
Average Value change %
0%
Average buys %
+0.001%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of LIGAND PHARMACEUTICALS INC - Common Stock (LGND)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 14.5% -6.88% $503M -$18.9M 2.84M -3.62% BlackRock, Inc. 30 Sep 2025
JANUS HENDERSON GROUP PLC 5.3% -3.33% $185M -$3.25M 1.04M -1.73% JANUS HENDERSON GROUP PLC 30 Sep 2025

Institutional Holders of LIGAND PHARMACEUTICALS INC - Common Stock (LGND)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 20.5M $3.63B +$253M $177.14 307
2025 Q2 19.2M $2.18B +$57.1M $113.68 268
2025 Q1 18.7M $1.97B +$46.6M $105.14 258
2024 Q4 18.2M $1.95B +$14.6M $107.15 255
2024 Q3 18.1M $1.81B +$78.1M $100.09 239
2024 Q2 17.3M $1.45B +$80.5M $84.26 231
2024 Q1 16.5M $1.21B +$33.9M $73.10 220
2023 Q4 16.1M $1.15B +$28.6M $71.42 207
2023 Q3 15.8M $946M +$7.78M $59.92 194
2023 Q2 15.6M $1.12B +$43.4M $72.10 202
2023 Q1 14.9M $1.1B +$24.8M $73.56 208
2022 Q4 14.7M $984M -$15.5M $66.80 194
2022 Q3 14.9M $1.28B -$9.22M $86.11 196
2022 Q2 14.9M $1.33B -$60.7M $89.22 183
2022 Q1 15.6M $1.76B -$96.5M $112.49 191
2021 Q4 16.3M $2.51B -$20.7M $154.46 213
2021 Q3 16.4M $2.29B +$72.1M $139.32 203
2021 Q2 15.9M $2.08B +$57.3M $131.19 208
2021 Q1 15.4M $2.35B -$1.01B $152.45 220
2020 Q4 22.8M $2.26B -$7.64M $99.45 232
2020 Q3 22.9M $2.18B +$68.8M $95.32 248
2020 Q2 22.1M $2.47B -$52.1M $111.85 253
2020 Q1 22.9M $1.67B -$13.5M $72.72 250
2019 Q4 22.7M $2.37B -$63.6M $104.29 254
2019 Q3 23.3M $2.32B -$162M $99.54 264
2019 Q2 24.9M $2.84B -$64.7M $114.15 298
2019 Q1 25.9M $3.25B -$121M $125.71 321
2018 Q4 26.8M $3.63B +$252M $135.70 352
2018 Q3 24.2M $6.64B -$320M $274.49 371
2018 Q2 25.6M $5.3B +$188M $207.17 341
2018 Q1 24.7M $4.07B +$62.2M $165.16 318
2017 Q4 24.7M $3.38B -$24.8M $136.93 295
2017 Q3 24.6M $3.35B -$39.8M $136.15 289
2017 Q2 25M $3.04B +$88.1M $121.40 260
2017 Q1 24.7M $2.61B +$250M $105.84 250
2016 Q4 24.8M $2.52B +$4.67M $101.61 264
2016 Q3 24.8M $2.53B +$83.7M $102.06 255
2016 Q2 24.7M $2.94B -$22.6M $119.27 263
2016 Q1 24.5M $2.63B +$143M $107.09 248
2015 Q4 23.2M $2.51B +$43M $108.42 231
2015 Q3 22.8M $1.95B -$18.5M $85.65 201
2015 Q2 21.6M $2.18B -$68.4M $100.90 213
2015 Q1 22.4M $1.73B +$78.9M $77.11 185
2014 Q4 21.7M $1.15B -$4.36M $53.21 178
2014 Q3 21.7M $1.02B +$29.3M $46.99 173
2014 Q2 20.6M $1.28B -$4.28M $62.29 191
2014 Q1 20.8M $1.4B +$26.3M $67.26 182